Furthermore, co-stimulation with α-GalCer further enhanced the anti-tumor function of anti-CD19 CAR-NKT cells, demonstrating that co-stimulation through CD1d and the CAR TCR can provide increased therapeutic benefit [111]. This evidence concerns the gene CD1D and neoplasm.